Isolation of antibodies from non-human primates for clinical use

Current Drug Discovery Technologies

Volumn 11, Issue 1, 2014, Pages 20-27

  Avril, Arnaud ^a   Froude, Jeffrey W ^a,b   Mathieu, Jacques ^a   Pelat, Thibaut ^a   Thullier, Philippe ^a  

^a INSTITUT DE RECHERCHE BIOMÉDICALE DES ARMÉES   (France)

^b U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

Author keywords

Antibodies; Chimpanzee; Clinical; Humanization; Macaque; Non human primates; Patent; Phage

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN;

ANTIBODY ISOLATION; ANTIBODY LIBRARY; ANTIBODY PRODUCTION; ARTICLE; CHIMPANZEE; HUMAN; LEGAL ASPECT; MACACA FASCICULARIS; NONHUMAN; PHAGE DISPLAY; PRIMATE; PRIORITY JOURNAL; RHESUS MONKEY;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOGLOBULIN FRAGMENTS; PEPTIDE LIBRARY; PRIMATES;

EID: 84899726878     PISSN: 15701638     EISSN: 18756220     Source Type: Journal    
DOI: 10.2174/15701638113109990030     Document Type: Article

References (47)

1. Bruggemann M, Neuberger MS. Strategies for expressing human antibody repertoires in transgenic mice. Immunol Today 1996; 17: 391-7.
2. Fishwild DM, O'Donnell SL, Bengoechea T, et al. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat Biotechnol 1996; 14: 845-51.
3. Tomizuka K, Shinohara T, Yoshida H, et al. Double transchromosomic mice: Maintenance of two individual human chromosome fragments containing Ig heavy and kappa loci and expression of fully human antibodies. Proc Natl Acad Sci USA 2000; 97: 722-7.
4. Van Meel FC, Steenbakkers PG, Oomen JC. Human and chimpanzee monoclonal antibodies. J Immunol Methods 1985; 80: 267-76.
5. Ehrlich PH, Moustafa ZA, Justice JC, et al. Human and primate monoclonal antibodies for in vivo therapy. Clin Chem 1988; 34: 1681-8.
6. Steiper ME, Young NM. Primate molecular divergence dates. Mol Phylogenet Evol 2006; 41: 384-94.
7. Goodman M, Grossman LI, Wildman DE. Moving primate genomics beyond the chimpanzee genome. Trends Genet 2005; 21: 511-7.
8. Chen Z, Chumakov K, Dragunsky E, et al. Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis. J Virol 2011; 85: 4354-62.
9. Chen Z, Earl P, Americo J, et al. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J Virol 2007; 81: 8989-95.
10. Chen Z, Earl P, Americo J, et al. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc Natl Acad Sci USA 2006; 103: 1882-7.
11. Chen Z, Moayeri M, Crown D, et al. Novel chimpanzee/human monoclonal antibodies that neutralize anthrax lethal factor, and evidence for possible synergy with anti-protective antigen antibody. Infect Immun 2009; 77: 3902-8.
12. Chen Z, Moayeri M, Zhao H, Crown D, Leppla SH, Purcell RH. Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding. Proc Natl Acad Sci USA 2009; 106: 13487-92.
13. Chen Z, Moayeri M, Zhou YH, et al. Efficient neutralization of anthrax toxin by chimpanzee monoclonal antibodies against protective antigen. J Infect Dis 2006; 193: 625-33.
14. Chen Z, Schneerson R, Lovchik J, et al. Pre-and postexposure protection against virulent anthrax infection in mice by humanized monoclonal antibodies to Bacillus anthracis capsule. Proc Natl Acad Sci USA 2011; 108: 739-44.
15. Goncalvez AP, Chien CH, Tubthong K, et al. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J Virol 2008; 82: 7009-21.
16. Goncalvez AP, Men R, Wernly C, Purcell RH, Lai CJ. Chimpanzee Fab fragments and a derived humanized immunoglobulin G1 antibody that efficiently cross-neutralize dengue type 1 and type 2 viruses. J Virol 2004; 78: 12910-8.
17. Men R, Yamashiro T, Goncalvez AP, et al. Identification of chimpanzee Fab fragments by repertoire cloning and production of a full-length humanized immunoglobulin G1 antibody that is highly efficient for neutralization of dengue type 4 virus. J Virol 2004; 78: 4665-74.
18. Schofield DJ, Glamann J, Emerson SU, Purcell RH. Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol 2000; 74: 5548-55.
19. Schofield DJ, Satterfield W, Emerson SU, Purcell RH. Four chimpanzee monoclonal antibodies isolated by phage display neutralize hepatitis a virus. Virology 2002; 292: 127-36.
20. Chahboun S, Hust M, Liu Y, et al. Isolation of a nanomolar scFv inhibiting the endopeptidase activity of botulinum toxin A, by single-round panning of an immune phage-displayed library of macaque origin. BMC Biotechnol 2011; 11: 113.
21. Chassagne S, Laffly E, Drouet E, Herodin F, Lefranc MP, Thullier P. A high-affinity macaque antibody Fab with human-like framework regions obtained from a small phage display immune library. Mol Immunol 2004; 41: 539-46.
22. Laffly E, Danjou L, Condemine F, et al. Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694. Antimicrob Agents Chemother 2005; 49: 3414-20.
23. Pelat T, Hust M, Hale M, Lefranc MP, Dubel S, Thullier P. Isolation of a human-like antibody fragment (scFv) that neutralizes ricin biological activity. BMC Biotechnol 2009; 9: 60.
24. Pelat T, Hust M, Laffly E, et al. High-affinity, human antibody-like antibody fragment (single-chain variable fragment) neutralizing the lethal factor (LF) of Bacillus anthracis by inhibiting protective antigen-LF complex formation. Antimicrob Agents Chemother 2007; 51: 2758-64.
25. Rulker T, Voss L, Thullier P, et al. Isolation and characterisation of a human-like antibody fragment (scFv) that inactivates VEEV in vitro and in vivo. PLoS One 2012; 7: E37242.
26. Schutte M, Thullier P, Pelat T, et al. Identification of a putative Crf splice variant and generation of recombinant antibodies for the specific detection of Aspergillus fumigatus. PLoS One 2009; 4: E6625.
27. Glamann J, Burton DR, Parren PW, et al. Simian immunodeficiency virus (SIV) envelope-specific Fabs with highlevel homologous neutralizing activity: Recovery from a long-termnonprogressor SIV-infected macaque. J Virol 1998; 72: 585-92.
28. Samuelsson A, Chiodi F, Ohman P, Putkonen P, Norrby E, Persson MA. Chimeric macaque/human Fab molecules neutralize simian immunodeficiency virus. Virology 1995; 207: 495-502.
29. Druar C, Saini SS, Cossitt MA, et al. Analysis of the expressed heavy chain variable-region genes of Macaca fascicularis and isolation of monoclonal antibodies specific for the Ebola virus' soluble glycoprotein. Immunogenetics 2005; 57: 730-8.
30. Anderson DR, Brams P, Hanna N, Shestowsky WS, Heard C. Treatment of psoriasis using anti-B7.1 (CD80) antibodies US patent 6,709,654, March 23, 2004.
31. Hanna N, Newman RA, Reff ME. Recombinant anti-CD4 antibodies for human therapy US patent 6,136,310, October 24, 2000.
32. Newman R, Hanna N, R. R Recombinant antibodies for human therapy. EP1266965, July 24, 1991.
33. Vinjamaram S, Czuczman MS, Hernandez-Ilizaliturri FJ. The use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma 2008; 8: 277-82.
34. Mason U, Aldrich J, Breedveld F, et al. CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. J Rheumatol 2002; 29: 220-9.
35. Quintas-Cardama A, O'Brien S. Targeted therapy for chronic lymphocytic leukemia. Target Oncol 2009; 4: 11-21.
36. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008; 8: 156-71.
37. Pelat T, Hust M, Thullier P. Obtention and engineering of nonhuman primate (NHP) antibodies for therapeutics. Mini Rev Med Chem 2009; 9: 1633-8.
38. Sblattero D, Bradbury A. A definitive set of oligonucleotide primers for amplifying human V regions. Immunotechnology 1998; 3: 271-8.
39. Barbas CF. Phage display : A laboratory manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, 2001; p 1 v. in various pagings.
40. Dübel S. Handbook of therapeutic antibodies. Wiley-VCH: Weinheim, 2007; p 3 v. (xxxiii, 1188 p.).
41. Krebber A, Bornhauser S, Burmester J, et al. Reliable cloning of functional antibody variable domains from hybridomas and spleen cell repertoires employing a reengineered phage display system. J Immunol Methods 1997; 201: 35-55.
42. Pelat T, Bedouelle H, Rees AR, Crennell SJ, Lefranc MP, Thullier P. Germline humanization of a non-human primate antibody that neutralizes the anthrax toxin, by in vitro and in silico engineering. J Mol Biol 2008; 384: 1400-7.
43. Ehrenmann F, Lefranc MP. IMGT/DomainGapAlign: IMGT standardized analysis of amino acid sequences of variable, constant, and groove domains (IG, TR, MH, IgSF, MhSF). Cold Spring Harb Protoc 2011; 2011: 737-49.
44. Thullier P, Chahboun S, Pelat T. A comparison of human and macaque (Macaca mulatta) immunoglobulin germline V regions and its implications for antibody engineering. MAbs 2010; 2: 528-38.
45. Thullier P, Huish O, Pelat T, Martin AC. The humanness of macaque antibody sequences. J Mol Biol 2010; 396: 1439-50.
46. Wild MA, Xin H, Maruyama T, et al. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat Biotechnol 2003; 21: 1305-6.
47. Abhinandan KR, Martin AC. Analyzing the "degree of humanness" of antibody sequences. J Mol Biol 2007; 369: 852-62.